Form SCHEDULE 13G/A AVADEL PHARMACEUTICALS Filed by: GENDELL JEFFREY L

February 6, 2026 5:55 PM UTC





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentages used in this Schedule 13G/A are calculated based upon the 98,153,471 ordinary shares, nominal value $0.01 per share, of Avadel Pharmaceuticals plc (the "Company") issued and outstanding at November 25, 2025, as set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on December 3, 2025. This Amendment No. 3 is being filed to report that the Reporting Persons (defined below) no longer beneficially own more than five percent of the outstanding ordinary shares of the Company. This Amendment No. 3 constitutes an exit filing for the Reporting Persons.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Tontine Asset Associates, LLC
 
Signature:Jeffrey L. Gendell
Name/Title:Managing Member
Date:02/06/2026
 
Tontine Capital Overseas Master Fund II, L.P.
 
Signature:Jeffrey L. Gendell
Name/Title:Managing Member of Tontine Asset Associates, LLC, the general partner of Tontine Capital Overseas Master Fund II, L.P.
Date:02/06/2026
 
Jeffrey L. Gendell
 
Signature:Jeffrey L. Gendell
Name/Title:Jeffrey L. Gendell
Date:02/06/2026


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

Jeffrey Gendell, 13G